BURLINGTON, ON, Oct. 2 /CNW/ - The Jenex Corporation (TSX Venture
Exchange: JEN) (Frankfurt: JNX) (at Yahoo Finance, use JEN.V) announced it
signed an exclusive agreement for the distribution of its Therapik(R) product
that relieves the pain and itch of insect bites and stings.
Felton Grimwade & Bickford Pty Ltd (FGB) of Oakleigh South 3167,
Australia will market Therapik in Australia and New Zealand.
The exclusive agreement between FGB and Jenex is for an initial five (5)
year term and is subject to the successful completion of the required
regulatory registration for Therapik prior to sale in Australia. FGB must meet
certain volume purchasing requirements each year of the agreement to maintain
their exclusivity in the territories.
Jenex President Michael Jenkins commented: "We look forward to working
with FGB as we continue to execute the commercialization phase of our
business. We believe FGB's market knowledge and experience in Australia and
New Zealand will help us meet and exceed our sales targets for these markets."
Mike McKelvie, CEO of FGB says: "We look forward to distributing
Therapik(R) to our many markets as a device to eliminate the pain and
discomfort of insect bites and stings. It is a product that every family
About Felton Grimwade & Bickford Pty Ltd: FGB is an independent
Australian owned and operated natural products company.
FGB manufactures and markets a range of essential oils, O.T.C.
pharmaceuticals, nutritional supplements, household products, personal care
products and medical devices in pharmacies and supermarkets throughout
Australia, and in a growing number of export markets. (www.fgb.com.au)
About The Jenex Corporation: Jenex has a non-invasive Medical Device that
prevents cold sore outbreaks. The interceptCS(TM) Cold Sore Prevention System
is approved in Canada and has received CE approval for European Union
In addition to interceptCS, Jenex markets Therapik(R) for insect stings &
bites. It could be described as "Sting No More". It immediately relieves the
pain & itch caused by stings & bites. Therapik is approved in Canada and the
United States, as well as having CE Mark.
Jenex's Thermal Therapy is patented in the U.S., Canada, Australia, &
The company's Mission statement: "Inform and educate the public about our
safe and effective products that have been clinically proven and approved to
provide improved life style benefits." Vision statement: "Commercialization of
our patented product line allowing Jenex to be the pre-eminent leader in cold
sore prevention and insect bite & sting relief." Jenex has the potential to
dominate two huge underdeveloped markets. Check www.interceptCS.com and
www.JenexCorp.com for details.
The TSX Venture Exchange Inc. has not reviewed and does not accept
responsibility for the accuracy or the contents of this press release. Certain
information included in this press release is forward-looking and is subject
to important risks and uncertainties. The results or events predicted in these
statements may differ materially from actual results or events.
For further information:
For further information: The Jenex Corporation, Michael A. Jenkins,
(905) 632-3830, email@example.com